Quantifying gadolinium-based nanoparticle uptake distributions in brain metastases via magnetic resonance imaging.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 May 2024
25 May 2024
Historique:
received:
22
01
2024
accepted:
16
05
2024
medline:
26
5
2024
pubmed:
26
5
2024
entrez:
25
5
2024
Statut:
epublish
Résumé
AGuIX, a novel gadolinium-based nanoparticle, has been deployed in a pioneering double-blinded Phase II clinical trial aiming to assess its efficacy in enhancing radiotherapy for tumor treatment. This paper moves towards this goal by analyzing AGuIX uptake patterns in 23 patients. A phantom was designed to establish the relationship between AGuIX concentration and longitudinal (
Identifiants
pubmed: 38796495
doi: 10.1038/s41598-024-62389-1
pii: 10.1038/s41598-024-62389-1
doi:
Substances chimiques
Gadolinium
AU0V1LM3JT
Contrast Media
0
Banques de données
ClinicalTrials.gov
['NCT04899908']
Types de publication
Journal Article
Clinical Trial, Phase II
Langues
eng
Sous-ensembles de citation
IM
Pagination
11959Informations de copyright
© 2024. The Author(s).
Références
Liu, Y. et al. Metal-based nanoenhancers for future radiotherapy: Radiosensitizing and synergistic effects on tumor cells. Theranostics 8, 1824–1849 (2018).
doi: 10.7150/thno.22172
pubmed: 29556359
pmcid: 5858503
Xie, J. et al. Emerging strategies of nanomaterial-mediated tumor radiosensitization. Adv. Mater. 31, 1802244 (2019).
doi: 10.1002/adma.201802244
Kempson, I. Mechanisms of nanoparticle radiosensitization. WIREs Nanomed. Nanobiotechnol. 13, e1656 (2021).
doi: 10.1002/wnan.1656
Das, P. & Das, M. K. Nanoparticle-based theranostics in cancer. In Multifunctional Theranostic Nanomedicines in Cancer (ed. Das, M. K.) 1–24 (Academic Press, 2021). https://doi.org/10.1016/B978-0-12-821712-2.00011-6 .
doi: 10.1016/B978-0-12-821712-2.00011-6
Neufeld, M. J., Lutzke, A., Pratx, G. & Sun, C. High-Z metal-organic frameworks for X-ray radiation-based cancer theranostics. Chem. Eur. J. 27, 3229–3237 (2021).
doi: 10.1002/chem.202003523
pubmed: 32902003
Detappe, A. et al. Key clinical beam parameters for nanoparticle-mediated radiation dose amplification. Sci. Rep. 6, 34040 (2016).
doi: 10.1038/srep34040
pubmed: 27658637
pmcid: 5034311
Cui, L. et al. Radiosensitization by gold nanoparticles: Will they ever make it to the clinic?. Radiother. Oncol. 124, 344–356 (2017).
doi: 10.1016/j.radonc.2017.07.007
pubmed: 28784439
Verry, C. et al. Theranostic AGuIX nanoparticles as radiosensitizer: A phase I, dose-escalation study in patients with multiple brain metastases (NANO-RAD trial). Radiother. Oncol. 160, 159–165 (2021).
doi: 10.1016/j.radonc.2021.04.021
pubmed: 33961915
Sancey, L. et al. The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy. Br. J. Radiol. 87, 20140134 (2014).
doi: 10.1259/bjr.20140134
pubmed: 24990037
pmcid: 4453146
Lux, F. et al. AGuIX (R) from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. Br. J. Radiol. 92, 20180365–20180365 (2018).
doi: 10.1259/bjr.20180365
pubmed: 30226413
pmcid: 6435081
Bianchi, A. et al. Targeting and in vivo imaging of non-small-cell lung cancer using nebulized multimodal contrast agents. Proc. Natl. Acad. Sci. USA 111, 9247–9252 (2014).
doi: 10.1073/pnas.1402196111
pubmed: 24927562
pmcid: 4078830
Dufort, S. et al. Nebulized gadolinium-based nanoparticles: A theranostic approach for lung tumor imaging and radiosensitization. Small 11, 215–221 (2015).
doi: 10.1002/smll.201401284
pubmed: 25201285
Sancey, L. et al. Long-term in vivo clearance of gadolinium-based AGuIX nanoparticles and their biocompatibility after systemic injection. ACS Nano 9, 2477–2488 (2015).
doi: 10.1021/acsnano.5b00552
pubmed: 25703068
Conti, A. et al. Empirical and Theoretical characterization of the diffusion process of different gadolinium-based nanoparticles within the brain tissue after ultrasound-induced permeabilization of the blood-brain barrier. Contrast Media Mol. Imaging 2019, 6341545 (2019).
doi: 10.1155/2019/6341545
pubmed: 31866799
pmcid: 6914891
Khan, M. et al. DOTAREM (DOTA)–gold-nanoparticles: Design, spectroscopic evaluation to build hybrid contrast agents to applications in nanomedecine. Int. J. Nanomed. 17, 4105–4118 (2022).
doi: 10.2147/IJN.S368458
Gerken, L. R. H. et al. Catalytic activity imperative for nanoparticle dose enhancement in photon and proton therapy. Nat. Commun. 13, 3248 (2022).
doi: 10.1038/s41467-022-30982-5
pubmed: 35668122
pmcid: 9170699
Thomas, E. et al. Ultrasmall AGuIX theranostic nanoparticles for vascular-targeted interstitial photodynamic therapy of glioblastoma. Int. J. Nanomed. 12, 7075–7088 (2017).
doi: 10.2147/IJN.S141559
Bort, G. et al. EPR-mediated tumor targeting using ultrasmall-hybrid nanoparticles: From animal to human with theranostic AGuIX nanoparticles. Theranostics 10, 1319–1331 (2020).
doi: 10.7150/thno.37543
pubmed: 31938067
pmcid: 6956799
Kotb, S. et al. Safety evaluation and imaging properties of gadolinium-based nanoparticles in nonhuman primates. Sci. Rep. 6, 35053–35053 (2016).
doi: 10.1038/srep35053
pubmed: 27725693
pmcid: 5057154
MD, A. A. A Double-Blind, Phase II Randomized Study of Brain-Directed Stereotactic Radiation With or Without AGuIX Gadolinium-Based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation Alone. https://clinicaltrials.gov/ct2/show/NCT04899908 (2022).
Verry, C. et al. Targeting brain metastases with ultrasmall theranostic nanoparticles, a first-in-human trial from an MRI perspective. Sci. Adv. 6, 5279 (2020).
doi: 10.1126/sciadv.aay5279
Bergen, R. V., Ryner, L. & Essig, M. Comparison of DCE-MRI parametric mapping using MP2RAGE and variable flip angle T1 mapping. Magn. Reson. Imaging https://doi.org/10.1016/j.mri.2020.01.001 (2020).
doi: 10.1016/j.mri.2020.01.001
pubmed: 32646633
Lavielle, A. et al. T1 mapping from MPRAGE acquisitions: Application to the measurement of the concentration of nanoparticles in tumors for theranostic use. J. Magn. Reson. Imaging 58, 313–323 (2023).
doi: 10.1002/jmri.28509
pubmed: 36315197
Marques, J. P. et al. MP2RAGE, a self bias-field corrected sequence for improved segmentation and T-1-mapping at high field. NeuroImage 49, 1271–1281 (2010).
doi: 10.1016/j.neuroimage.2009.10.002
pubmed: 19819338
Jacques, V. et al. High relaxivity MRI contrast agents part 2: Optimization of inner- and second-sphere relaxivity. Invest. Radiol. 45, 613–624 (2010).
doi: 10.1097/RLI.0b013e3181ee6a49
pubmed: 20808234
pmcid: 3024144
Welcome to qMRLab’s documentation!—qMRLab 0.1 documentation. https://qmrlab.readthedocs.io/en/master/ .
Fram, E. K. et al. Rapid calculation of T1 using variable flip angle gradient refocused imaging. Magn. Reson. Imaging 5, 201–208 (1987).
doi: 10.1016/0730-725X(87)90021-X
pubmed: 3626789
Tran, V.-L. et al. Quantitative tissue pharmacokinetics and EPR effect of AGuIX nanoparticles: A multimodal imaging study in an orthotopic glioblastoma rat model and healthy macaque. Adv. Healthc. Mater. 10, 2100656 (2021).
doi: 10.1002/adhm.202100656